BioSpace News Archive

CytomX Therapeutics, Inc. today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

PMV Pharmaceuticals, Inc. announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in a panel discussion on lung cancer at the 42nd Annual Cowen Health Care Conference taking place virtually March 7-9, 2022.

Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the first patient has been dosed in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that Charlene Liao, Ph.D., chief executive officer of Immune-Onc, will host virtual one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference and will deliver a company presentation at the Oppenheimer 32nd Annual Healthcare Conference.

Bruker Corporation (Nasdaq: BRKR) announced its TIMS DIA-NN software for the high-throughput, deep and unbiased 4D proteomics workflow. It now features the novel TIMScore algorithm which takes advantage of machine learning (ML) to predict CCS values of tryptic and phosphorylated peptides.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities Life Sciences AI Symposium on Tuesday, March 1, 2022, at 10:10 a.m. ET.

Increasing funds from public and private organizations, rising demand for vaccines and molecular therapy, and rapid advancements in biomedical technology are key factors expected to drive global Biologics market revenue growth.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference.